Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

LEUVEN, Belgium and LUND, Sweden, February 23 /PRNewswire-FirstCall/ --

- Trial to Assess the Benefits of Partial Factor VIII Inhibition in Patients Undergoing Knee Replacement Surgery

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.

TB-402 is a recombinant human monoclonal antibody that targets Factor VIII, a key component of the coagulation cascade. TB-402 is a novel anticoagulant agent, which may deliver important clinical benefits due to it only partially inhibiting Factor VIII activity even when given in very high doses. This novel mode of action is expected to reduce the risk of undesirable bleeding events and the need for patient monitoring, the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent which means that patients are expected to receive just one single dose after surgery to prevent the development of DVT, as opposed to all current treatment options which require daily treatment for up to several weeks.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The trial will enrol 300 patients across 36 centers mainly in Central Europe. The primary endpoint is the safety and efficacy of the three
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , 2 de octubre de 2014 Laborie ... Toronto, Ontario , ha completado la adquisición de ... Inc. Unisensor tiene su sede central sita en Wiesendangen, ... en Portsmouth, New Hampshire . Unisensor ... micro de alta resolución para evaluar la presión y ...
(Date:10/2/2014)... MUMBAI, India , October 2, 2014 ... (CRO) showcased its biometrics capabilities at the prestigious Annual ... 2014 in Las Vegas , where ... experts presented on varied topics like ,data analytics to ... stage / registry studies, and ,benefits of working together ...
(Date:10/1/2014)... , Oct. 1, 2014  Pressure BioSciences, Inc. ... in the development and sale of high pressure-based sample ... announced it has been invited to present at the ... Warsaw , Poland.  The Conference will take ... 2014.  Mr. Richard T. Schumacher , President and ...
(Date:10/1/2014)... As the world takes its first steps into the ... century would mark the beginning of a new era of ... fact that the world is experiencing a rapid rise in ... Almost half of these chronic conditions are due to lifestyle ... care and intervention. While the world is experiencing a rapid ...
Breaking Biology Technology:LABORIE adquiere Unisensor AG y Unisensor USA, Inc. 2SIRO Clinpharm Showcases Biometrics Capabilities at the SCDM 2014 Annual Conference in Las Vegas 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 2Fighting Mortality and Morbidity of Chronic Health Disorders during Open Access Week 3
... Inc. enters into an exclusive, distribution agreement with AZPA International Inc. ... ... Zealand -, LAVAL, QC, Dec. 19 /PRNewswire-FirstCall/ - Neptune ... it has entered into an exclusive distribution agreement with,AZPA International Inc. ...
... Calif., Dec. 19 SleepQuest, the leader in,at-home ... the,launch of an improved version of its main ... support its community of,patients, family members, and healthcare ... testing and sleep apnea,treatment, we have redesigned our ...
... Nonin Medical, Inc., a leading,innovator of ... Practices Award for Product Differentiation Innovation from ... industry achievements and,the Awards are recognized worldwide ... markets. The global growth consulting company honored ...
Cached Biology Technology:Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand 2Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand 3SleepQuest Launches Updated Web Site 2Nonin Medical, Inc. Receives Frost & Sullivan's 2007 Award for Product Differentiation Innovation 2Nonin Medical, Inc. Receives Frost & Sullivan's 2007 Award for Product Differentiation Innovation 3
(Date:9/30/2014)... at the University of California, San Diego, have completed ... using a method that uses the pixels in an ... known as mesh-free simulation. , The researchers, led by ... at the Jacobs School of Engineering at UC San ... method at the CompIMAGE,14 conference in Pittsburgh this month. ...
(Date:9/30/2014)... September 30, 2014--Sea monkeys have captured the popular attention ... easily observable life cycle -- sold as dehydrated eggs, ... given little more than a tank of salt water. ... pattern: Like other zooplankton, brine shrimp vertically migrate in ... closer to the surface at night and retreating deeper ...
(Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
Breaking Biology News(10 mins):First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Contaminated water linked to pregnancy complications, BU study finds 2
... - Eurofins MWG Operon, a leader in next ... services with the Ion Proton Next Generation Sequencer. ... was also awarded after joining Life Technologies Corporation,s ... Membership in Life Technologies, CSP program is exclusive ...
... This 2014 FASEB Science Research Conference focuses on ... transduction cascades, lipid mediators, and lipid targets that ... initiation and progression of human cancers. ... scientists and scientists from industry for presentations, discussion, ...
... world,s cartilaginous fish, namely sharks and rays, face extinction ... study to systematically and globally assess their fate. ... Specialist Group (SSG), co-chaired by Nick Dulvy, a Simon ... and Conservation in British Columbia, conducted the study. ...
Cached Biology News:Study says sharks/rays globally overfished 2
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
... Chemicon Detergent-OUT Kit is a simple high ... solutions. Removes detergents without significant dilution ... protein solution on the Detergent-OUT Spin column ... columns are suitable for removing detergent from ...
... The standard electrophoresis hood is ... documentation systems. Placed on the ... in place and provides a ... on the lab bench. This ...
... SDS Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... columns are suitable for removing detergent from ...
Biology Products: